查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
RNAi技术市场按应用（药物发现和开发,治疗）,地区（北美,欧洲,亚太,中东和非洲,南美）,规模,份额,展望,机会分析2022-2028
市场调查报告书
商品编码
1149833

RNAi技术市场按应用（药物发现和开发,治疗）,地区（北美,欧洲,亚太,中东和非洲,南美）,规模,份额,展望,机会分析2022-2028

RNAi Technology Market, By Application (Drug Discovery and Development and Therapeutics), By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028
出版日期: | 出版商: Coherent Market Insights | 英文 165 Pages | 商品交期: 2-3个工作天内

价格
简介目录

近年来，利用RNA的治疗方法备受关注，有望治疗心血管疾病、癌症、糖尿病、肺结核、艾滋病等多种疾病，以及罕见病和遗传病。RNAi 也有望治疗病毒性疾病，如人类免疫缺陷病毒 (HIV) 和丙型肝炎病毒 (HCV)。此外，RNAi 目前用于生物学和生物医学研究，以检查阻断特定基因表达的影响。

市场动态。

慢性病患病率上升、对 RNAi 疗法开发的关注度增加、分子诊断中应用数量的增加、RNAi 疗法的频繁批准、预计在预测期内爆发的 COVID-19 是预计将推动全球增长的主要因素RNAi 技术市场。

例如，2022 年 6 月，Alnylam Pharmaceuticals, Inc 宣布每三个月皮下注射一次，用于治疗成人遗传性转甲状腺素蛋白介导的 (hATTR) 淀粉样变性多发性神经病。美国食品和药物管理局 (FDA) 已宣布将要给药的 RNAi 治疗药物“AMVUTTRA”已获得批准。此外，2018 年 8 月，美国食品和药物管理局 (FDA) 批准了 Alnylam Pharmaceuticals 的 Onpattro，这是一种 RNAi 疗法，用于治疗患有一种罕见的致命遗传病，称为遗传性转甲状腺素蛋白介导的淀粉样变性病。我来了。

这项研究的主要特点

  • 本报告对全球 RNAi 技术市场进行了深入分析，提供了以 2021 年为基准年的预测期 (2022-2028) 的市场规模和復合年增长率 (CAGR%)。
  • 它还揭示了不同细分市场的潜在创收机会，并描述了该市场具有吸引力的投资建议矩阵。
  • 它还提供了有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景、主要参与者采用的竞争战略等方面的重要见解。
  • 根据公司亮点、产品组合、主要亮点、财务业绩和战略等参数，了解全球 RNAi 技术市场主要参与者的概况。
  • 本研究涵盖的主要公司包括 Dicerna Pharmaceuticals Inc.、Phio Pharmaceuticals Corp.、Arcturus Therapeutics、Ionis Pharmaceuticals Inc.、Sigma Aldrich (Merck KGaA)、Benitec Biopharma Ltd.、Silence Therapeutics PLC、QIAGEN、SBI Biotech Co. Ltd.、Alnylam Pharmaceuticals Inc. 和 Thermo Fisher Scientific Inc. 等。
  • 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。.
  • 全球 RNAi 技术市场报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
  • 利益相关者可以通过用于分析全球 RNAi 技术市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

  • 调查目的
  • 先决条件
  • 缩写说明

第二章市场展望

  • 报告内容
    • 市场定义和范围
  • 执行摘要
    • 市场概况：按应用分类
    • 市场概况：按地区
  • 连贯机会图 (COM)

第3章市场动态、规律及趋势分析

  • 市场动态
    • 增加对 RNAi 疗法的认可
    • 严格的规章制度
    • COVID-19 爆发（大流行）
  • 影响分析
  • 主要亮点
  • 监管情景
  • 产品发布/批准
  • 害虫分析
  • 对 PORTER 的分析
  • 合併/收购场景

第 4 章 RNAi 技术的全球市场 - 冠状病毒 (COVID-19) 大流行的影响

  • COVID-19 的流行病学特征
  • 供应方和需求方分析
  • 经济影响

第 5 章 RNAi 技术的全球市场，按应用分类，2017-2028

  • 药物发现和开发
  • 治疗药物

第 6 章。2017-2028 年按地区分列的 RNAi 技术全球市场

  • 北美
  • 欧洲
  • 亚太地区
  • 世界其他地方

第七章竞争格局

  • QIAGEN
  • Dicerna Pharmaceuticals Inc.
  • Phio Pharmaceuticals Corp.
  • Arcturus Therapeutics
  • Ionis Pharmaceuticals Inc.
  • Sigma Aldrich（Merck KGaA）
  • Benitec Biopharma Ltd.
  • Silence Therapeutics PLC
  • SBI Biotech Co. Ltd.
  • Alnylam Pharmaceuticals Inc.
  • Thermo Fisher Scientific Inc.

第 8 章

  • 调查方法介绍
  • 关于出版商
简介目录
Product Code: CMI5281

RNA based therapeutics have garnered significant attention in recent years due to its potential to treat a variety of disease such as cardiovascular disease, cancer, diabetes, TB, AIDS, as well as rare and genetic disorders. RNAi also has the potential to treat viral diseases such as those caused by the human immunodeficiency virus (HIV) and hepatitis C virus (HCV). Moreover, RNAi is now being used in biological and biomedical research to study the effect of blocking expression of a given gene.

Market Dynamics:

Increasing prevalence of chronic diseases, rise in focus on RNAi therapeutic development, rise in number of applications in molecular diagnostics, frequent approvals of RNAi therapeutics, and the outbreak of COVID-19 are major factors expected to drive growth of the global RNAi technology market over the forecast period.

For instance, in June 2022, Alnylam Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) approved AMVUTTRA, an RNAi therapeutic administered via subcutaneous injection once every three months for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Moreover, in August 2018, The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals' Onpattro, an RNAi therapeutic for individuals with a rare and deadly genetic disorder called hereditary transthyretin-mediated amyloidosis.

Key features of the study:

  • This report provides in-depth analysis of the global RNAi technology market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global RNAi technology market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key companies covered as a part of this study include Dicerna Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Arcturus Therapeutics, Ionis Pharmaceuticals Inc., Sigma Aldrich (Merck KGaA), Benitec Biopharma Ltd., Silence Therapeutics PLC, QIAGEN, SBI Biotech Co. Ltd., Alnylam Pharmaceuticals Inc., and Thermo Fisher Scientific Inc., among others.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global RNAi technology market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global RNAi technology market.

Detailed Segmentation:

  • Global RNAi Technology Market, By Application:
    • Drug Discovery and Development
    • Therapeutics
  • Global RNAi Technology Market, By Geography:
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and Africa
    • South America
  • Company Profiles:
    • QIAGEN
    • Dicerna Pharmaceuticals Inc.
    • Phio Pharmaceuticals Corp.
    • Arcturus Therapeutics
    • Ionis Pharmaceuticals Inc.
    • Sigma Aldrich (Merck KGaA)
    • Benitec Biopharma Ltd.
    • Silence Therapeutics PLC
    • SBI Biotech Co. Ltd.
    • Alnylam Pharmaceuticals Inc.
    • Thermo Fisher Scientific Inc.

Table of Contents:

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Application
    • Market Snapshot, By Geography
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Increasing approvals for RNAi therapeutics
    • Stringent rules and regulations
    • The outbreak of COVID-19 (pandemic)
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product launch/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global RNAi Technology Market - Impact of Coronavirus (Covid-19) Pandemic

  • COVID-19 Epidemiology
  • Supply Side and Demand Side Analysis
  • Economic Impact

5. Global RNAi Technology Market, By Application, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • Drug Discovery and Development
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
  • Therapeutics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)

6. Global RNAi Technology Market, By Geography, 2017-2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2022 and 2028 (%)
    • Y-o-Y Growth Analysis, 2017 - 2028
    • Segment Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)
  • Rest of World
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017-2028,(US$ Mn)
    • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017-2028,(US$ Mn)

7. Competitive Landscape

  • QIAGEN
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Dicerna Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Phio Pharmaceuticals Corp.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Arcturus Therapeutics
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Ionis Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sigma Aldrich (Merck KGaA)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Benitec Biopharma Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Silence Therapeutics PLC
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • SBI Biotech Co. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Alnylam Pharmaceuticals Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Thermo Fisher Scientific Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Analyst Views

8. Section

  • Research Methodology
  • About us